Do you want to read an article? Please log in or register.
Outcome of COVID-19 in Patients with Autoimmune Hepatitis: an International Multi-Centre Study
Hepatitis
Related content
Further Publications
Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study
Clin Gastroenterol Hepatol
Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen V, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin K, Zhou K, Lizaola-Mayo B, Moghe A, Debes J, Lee TH, Branch A, Viveiros K, Chan W, Chascsa D, Kwo P, Dhanasekaran R
doi: 10.1016/j.cgh.2020.09.027
Inflammatory Bowel Disease
Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force
J Crohns Colitis
Dotan I, Panaccione R, Kaplan GG, O'Morain C, Lindsay JO, Abreu MT, IOIBD.
doi: 10.1093/ecco-jcc/jjaa147
Further Publications
AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19
Gastroenterology.
Sultan S, Altayar O, Siddique SM, Davitkov P, Feuerstein JD, Lim JK, Falck-Ytter Y, El-Serag HB, AGA.
doi: 10.1053/j.gastro.2020.05.001.
COMMENTED
Inflammatory Bowel Disease
Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Gastroenterology.
Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD
doi: 10.1053/j.gastro.2020.05.032.
Hepatology
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19
J Hepatol.
Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J
doi: 10.1016/j.jhep.2020.05.002.
Hepatitis
Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group
J Hepatol.
Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D, Manns MP, Vesterhus M, European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and of the International Autoimmune Hepatitis Group (IAIHG)
doi: 10.1016/j.jhep.2020.07.023.
Hepatology
Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19
Gut.
Yip TC, Lui GC, Wong VW, Chow VC, Ho TH, Li TC, Tse YK, Hui DS, Chan HL, Wong GL
doi: 10.1136/gutjnl-2020-321726.
Hepatology
Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey
United European Gastroenterol J
Zecher BF, Buescher G, Willemse J, Walmsley M, Taylor A, Leburgue A, Schramm C, Lohse AW, Sebode M
doi: 10.1002/ueg2.12100
Inflammatory Bowel Disease
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study
Lancet Gastroenterol Hepatol
Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA, PROTECT-ASUC Study Group.
doi: 10.1016/S2468-1253(21)00016-9